Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Canada.
Division of General Internal Medicine, Department of Medicine, McGill University Health Centre, Montreal, Canada; Division of Experimental Medicine, McGill University, Montreal, Canada.
Ann Epidemiol. 2021 Mar;55:24-26. doi: 10.1016/j.annepidem.2020.12.002. Epub 2020 Dec 16.
The purpose of this study was to examine whether the latest National Institute for Health and Care Excellence proton pump inhibitor (PPI) guidelines changed physician prescribing patterns in clinical practice.
Using data from the United Kingdom Clinical Practice Research Datalink, we calculated monthly PPI prescribing rates in adults by dividing the number of PPI prescriptions by the number of patients in each calendar month. Using these rates, we conducted an interrupted time-series analysis to compare PPI prescription rates before (September 2010-August 2014) and after (September 2014-August 2018) guideline publication, estimating a slope and level change using segmented autoregression.
In the preguideline period, monthly PPI prescription rate increased by 46.9 (95% confidence interval (CI): 40.8 to 53.0) prescriptions per 100,000 persons. Following guideline publication, there was no immediate change in the monthly PPI prescribing rate (137.6, 95% CI: -36.7 to 311.9 prescriptions per 100,000 persons), but there was a modest attenuation of the change in monthly rate (-23.9, 95% CI: -14.0 to -33.6 prescriptions per 100,000 persons). However, the predicted rates mirror the observed rates after guideline publication, suggesting limited changes.
Despite efforts to minimize the overprescribing of PPIs, there was little meaningful change in clinical practice following the 2014 National Institute for Health and Care Excellence recommendations.
本研究旨在探讨最新的英国国家卫生与保健优化研究所质子泵抑制剂(PPI)指南是否改变了临床实践中的医生处方模式。
我们利用英国临床实践研究数据链的数据,通过将 PPI 处方数量除以每个日历月的患者数量,计算出成年人每月的 PPI 处方率。利用这些比率,我们进行了一项中断时间序列分析,比较了指南发布前后(2010 年 9 月至 2014 年 8 月和 2014 年 9 月至 2018 年 8 月)的 PPI 处方率,使用分段自回归估计斜率和水平变化。
在指南发布前的时期,每月 PPI 处方率增加了 46.9(95%置信区间(CI):40.8 至 53.0)剂/每 10 万人。在指南发布后,每月 PPI 处方率没有立即发生变化(137.6,95%CI:每 10 万人 -36.7 至 311.9 剂),但每月率的变化幅度略有减弱(-23.9,95%CI:每 10 万人 -14.0 至 -33.6 剂)。然而,发布指南后预测的比率与观察到的比率相符,表明变化有限。
尽管努力尽量减少 PPI 的过度处方,但在 2014 年英国国家卫生与保健优化研究所的建议发布后,临床实践几乎没有发生有意义的变化。